A collaborative venture bringing together experts in bladder cancer and drug development
Chief Executive Officer
As CEO of CicloMed LLC, Ms. Ham leads a team of experts committed to developing and commercializing an innovative, less-invasive approach to fighting bladder cancer. Since 2015 she has served as President of CicloMed’s parent company, BioNovus Innovations LLC, which is building a portfolio of organizations to advance scientific discoveries into transformational improvements in healthcare. Ms. Ham started her career as a Registered Nurse in hospitals and outpatient settings, then became a clinical administrator. In 1997, she founded Ambulatory Surgery Assistance, Inc., which developed more than 30 ambulatory surgery centers. After selling that company to Nueterra Healthcare in 2005, Ms. Ham served in increasingly responsible executive roles with Nueterra. She is a Registered Nurse graduate of Saint Luke’s College of Nursing. Ms. Ham also serves as a mentor with Techstars and a board member of Operation Breakthrough.
William McCulloch, M.B., Ch.B., F.R.C.P., F.F.P.M.
Acting Chief Medical Officer and Chair of the Clinical Advisory Board
Dr. McCulloch brings to his role as CicloMed’s Chief Medical Officer more than three decades of experience in pharmaceutical research and development, as an executive and consultant to large and small companies focusing on cancer and serious infectious diseases. He has undertaken all phases of drug and technology development, and has been directly involved in filing INDs and NDAs, securing Orphan Drug status for compounds, and obtaining SBIR and other grant funding. As co-founder and president of Alba BioPharm Advisors since 2002, Dr. McCulloch has provided consulting services in drug development, oncology and regulatory affairs for clients. He earned his medical degree at the University of Glasgow and practiced medicine in the United Kingdom for seven years before entering the industry.
Scott J. Weir, Pharm.D., Ph.D.
Acting Chief Scientific Officer
Dr. Weir brings 32 years of drug discovery and development experience to CicloMed. He is a professor at the University of Kansas Medical Center, Director of the Institute for Advancing Medical Innovation (IAMI) at KU, and Associate Director of Translational Research for The University of Kansas Cancer Center. He is a co-discoverer of Ciclopirox Prodrug, the anticancer agent that CicloMed is developing. Since joining KU in 2006, Dr. Weir has established and managed a fully integrated program to discover promising new agents for the treatment and prevention of cancer, and to advance potential new drugs discovered at the university from bench to bedside. From 1986 to 2006, Dr. Weir served in leadership positions in several global pharmaceutical companies, contributing to successful development and regulatory approvals for a number of drug products. He earned his Pharm.D. degree from the University of Nebraska College of Pharmacy, followed by a Ph.D. in pharmacokinetics and biopharmaceutics from the University of Nebraska Medical Center.
Mike Dalton, Pharm.D.
Chief Regulatory Officer
Dr. Dalton has more than 25 years of experience in clinical development and regulatory affairs, assisting pharmaceutical and biotech clients in all phases of regulatory strategy development. He is a founding partner of The Gnomon Group. In his consulting capacity and previous positions with Burroughs Wellcome, GlaxoWellcome, PharmaResearch and Triangle/Gilead, he has had a leadership role in at least 15 NDA approvals and many supplemental NDAs, as well as helping file more than 50 INDs and serving as FDA contact and liaison. He has also served as head of pharmacovigilance at several companies and advises companies on drug safety. Dr. Dalton earned a bachelor’s degree from the University of Nebraska at Omaha School of Pharmacy and a Pharm.D. from the University of Michigan. He completed a clinical fellowship with the University of North Carolina at Chapel Hill School of Pharmacy and Burroughs Wellcome Company in Research Triangle Park. He also served as an officer in the U.S. Army and worked as a staff pharmacist at Veterans Administration hospitals.
Robyn Wood, B.G.S.
Ms. Wood has over 30 years of drug development experience and has worked since 2009 as project director for the Institute for Advancing Medical Innovation (IAMI) at the University of Kansas Medical Center. A University of Kansas alumna, she spent 17 years with INTERx Research/Merck as a Research Biologist, later moving to Oread Pharmaceuticals and Quintiles. At Quintiles, Ms. Wood was hired as the first project manager to support drug development projects and while there she moved into a senior director position. When Aptuit acquired the early drug development business of Quintiles, she moved from director of pharmaceutical services project manager to global director of client services for Aptuit.